AML-027 The LD-VenEx Phase II Clinical Trial: An ex Vivo Flow Cytometry Based-Drug Screening of AML Patient Samples

Autor: Katyayini, Niveditha Umesh, Gordon, Sandra Leigh, Kuusanmäki, Heikki A, Durán, Pilar Ayuda, Enserink, Jorrit Martijn, Wennerberg, Krister

Publikováno v: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S260-S261

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells.

Autor: Zhang B; Oslo University Hospital, Montebello, Oslo, Norway., Durán PA; Oslo University Hospital, Montebello, Oslo, Norway., Piechaczyk L; Oslo University Hospital, Montebello, Oslo, Norway., Fløisand Y; Oslo University Hospital, Montebello, Oslo, Norway., Safont MMS; University of Bergen, Bergen, Norway., Karlsen IT; University of Bergen, Bergen, Norway., Fandalyuk Z; University of Bergen, Bergen, Norway., Tadele D; Oslo University Hospital, Montebello, Oslo, Norway., Mierlo PV; Oslo University Hospital, Montebello, Oslo, Norway., Rowe AD; Oslo University Hospital, Rikshospitalet, Norway., Robertson JM; Oslo University Hospital, Montebello, Oslo, Norway., Gjertsen BT; University of Bergen, Bergen, Norway., McCormack E; University of Bergen, Bergen, Norway., Enserink JM; Oslo University Hospital, Montebello, Oslo, Norway; jorrit.enserink@rr-research.no.

Publikováno v: Haematologica [Haematologica] 2018 May 10; Vol. Online ahead of print. Date of Electronic Publication: 2018 May 10.